Oncology Clinical Biomarker Lead, Translational Development at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

In-depth understanding of solid tumor oncology with knowledge of current and evolving clinical landscape and competitive scenarios
Strong scientific background with understanding of clinical, translational, and mechanistic data with proven track record of publications
Understanding of early or late-stage drug and translational development process; including experience with implementing a biomarker strategy
Clinical protocol authoring and review of regulatory documents
Working knowledge of technological platforms covering biomarker measures including but not limited to genomics, gene expression, immune profiling, and flow cytometry
Excellent data analysis and problem-solving skills
Exceptional verbal and written communication skills with experience in developing written documents such as primary manuscripts/publications/reviews, scientific presentations and regulatory submissions (INDs/NDAs) with ability to synthesize complex scientific concepts into simple communication points
Proven scientific/project leadership expertise and experience working in global teams and managing people/projects

Responsibilities

Integrate translational research and clinical development, developing biomarker strategies in alignment with clinical development objectives
Lead efforts for data generation and interpretation and for communication to the development team
Act as a lead scientist to implement and deliver on biomarker strategies for clinical programs
Develop reports and publications on translational data generated to support asset development
Contribute to regulatory submissions
Work on cross-functional project teams to drive execution of translational/biomarker plans working with disease and lab scientists, as well as BMS members from clinical, medical, commercial, regulatory, and diagnostics
Engage with external academic collaborators/Key Opinion Leaders (KOLs)

Skills

Clinical Biomarkers

Translational Development

Oncology

Immuno-oncology

Solid Tumors

Tumor Biology

Immune Biology

Predictive Biomarkers

Biomarker Strategy

Clinical Development

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free